ArticleBlood2022

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.

Tanya Siddiqi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.